Tyme Technologies Announces Launch of a Pancreatic Research Program with the Mayo Clinic Led by Dr. Martin Fernandez-Zapico

NEW YORK, Dec. 13, 2016 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (“Tyme” or “the Company”) (OTCQB:TYMI), a clinical-stage pharmaceutical company focused on developing highly targeted cancer therapeutics for a broad range of oncology indications, today announced the launch of a Pancreatic Research Program with the Mayo Clinic led by Dr. Martin Fernandez-Zapico.

Dr. Martin E. Fernandez-Zapico, Associate Professor of Medicine and Pharmacology at the Mayo Clinic, is an international expert in the field of pancreatic cancer, a disease predicted to be the second leading cause of cancer in 2030. Dr. Fernandez-Zapico's programs are affiliated with the Mayo Clinic Cancer Center, Department of Oncology, Division of Gastroenterology and Hepatology, and the Center for Cell Signaling in Gastroenterology. His research is supported by the National Institutes of Health (NIH), the NIH-funded Mayo Clinic Pancreatic Cancer Specialized Program of Research Excellence (SPORE), the NIH-funded Mayo Clinic Center for Cell Signaling in Gastroenterology, and the Leukemia and Lymphoma Foundation. His work has been seminal for the understanding of mechanisms driving this malignancy and serves as a foundation for multiple National Cancer Institute sponsored clinical trials. 

"Tyme is extremely pleased to be working with Dr. Fernandez-Zapico of the Mayo Clinic in an effort to potentially discover the future cure of pancreatic cancer.  I believe the pancreatic research experiments planned by Dr. Fernandez-Zapico, using our proprietary discoveries and supported by Tyme, could lead to significant progress in battling this devastating form of cancer.  We look forward to continuing our clinical development program in pancreatic and other cancers, based on collaborations with Mayo and other leading institutions," said Dr. Del Priore, Chief Medical Officer of Tyme.

About Tyme

Our research and development efforts are based on patented technologies and our patent pending proprietary platform technology, for which we retain global IP and commercial rights.  Our lead program is SM-88, a proprietary combination drug product.  We believe SM-88 is a first-in-class oncology therapy that increases the power of the body’s innate defenses to utilize oxidative stress to kill cancer cells.  SM-88 is designed to penetrate only living cancer cells without toxic effects and without involving healthy body tissue.  We believe that SM-88’s therapeutic potential is based on its ability to increase the availability of free radicals and promote their entry into cancer cells by stripping the cancer cells of their normal barriers to these toxic electrons.  SM-88 is a combination of a proprietary novel molecule with three currently-marketed drugs that are generally considered safe for their already approved indications, which are in areas other than cancer treatment.

Forward-Looking Statements

In addition to historical information, this press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, and Section 21E of the U.S. Securities Exchange Act of 1934.  Such forward-looking statements may include projections regarding Tyme’s future performance, and readers can identify forward-looking statements by sentences or passages involving the use of terms such as "anticipates," "believes," “designed,” "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "would" and similar expressions intended to identify forward-looking statements.  The forward-looking statements contained in this press release are based on management's current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of Tyme’s control.  Forward-looking statements within this press release include, without limitation, statements regarding our drug development strategies, the therapeutic mechanisms of our drug candidates and our completed and planned clinical trials.  These statements involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance or achievements to be materially different from any historical results and future results, performances or achievements expressed or implied by the forward-looking statements.  These risks and uncertainties include, but are not limited to, the factors described in the section captioned "Risk Factors" of Tyme's Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission on March 30, 2016 (available at www.sec.gov).

CONTACT: Contact:

Lisa Wilson
In-Site Communications, Inc.
T: (212) 452-2793
E: lwilson@insitecony.com

Ads